Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic User Fee Talks Reach 'Final Wording' But Still Not Done

Executive Summary

FDA and industry say they have reached tentative agreement, but finance subgroup says more discussion needed.


Related Content

GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began
ANDA User Fees Offer Sponsor Relief, But More Facility Pain
Will PDUFA VI Fee Structure Changes Slow Revenue Growth?
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
US FDA Lays Out High And Low Options At MDUFA Talks
Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed
GDUFA II: FDA, Industry Reach Tentative 'Alignment' On ANDA Review Issues
PDUFA Negotiations End, Approval Process Ongoing
GDUFA II: Facility Fees Might Be Deferred Until ANDA Approval
FDA's GDUFA War Chest Grows, And Industry May Look For Lower Fees





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts